Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmacyclics, a developer of novel pharmaceutical products to treat oncology and autoimmune diseases, has appointed Ahmed Hamdy as its new chief medical officer.
Subscribe to our email newsletter
Dr Hamdy most recently served as therapeutic area head at Elan Pharmaceuticals responsible for gastroenterology and autoimmune clinical development.
Dr Hamdy has also served as the general medicine therapeutic area head at PDL BioPharma from February 2006 to June 2008. Dr Hamdy has received his MD (MBBCh) from Cairo University, Egypt.
Glenn Rice, COO and president of Pharmacyclics, said: “Dr Hamdy has deep and broad industry experience and has shown time and time again that he can deliver high quality clinical studies in a timely manner and successfully represent these studies to the FDA. We are pleased to have him on board to guide our extensive clinical portfolio of cancer and autoimmune therapeutics.”